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Abstract
Background: Dementia with Lewy bodies (DLB) and dementia in Parkinson’s disease (PDD) are recognised to be
under-recognised in clinical practice in the UK, with only one third to a half of expected cases diagnosed. We
aimed to assess whether clinical diagnostic rates could be increased by the introduction of a structured assessment
toolkit for clinicians.
Methods: We established baseline diagnostic rates for DLB and PDD in four memory clinics and three movement
disorder/Parkinson’s disease (PD) clinics in two separate geographical regions in the UK. An assessment toolkit
specifically developed to assist with the recognition and diagnosis of DLB and PDD was then introduced to the
same clinical teams and diagnostic rates for DLB and PDD were reassessed.
For assessing DLB diagnosis, a total of 3820 case notes were reviewed before the introduction of the toolkit, and
2061 case notes reviewed after its introduction. For PDD diagnosis, a total of 1797 case notes were reviewed before
the introduction of the toolkit and 3405 case notes after it. Mean values and proportions were analysed using
Student’s t test for independent samples and χ2 test, respectively.
Results: DLB was diagnosed in 4.6% of dementia cases prior to the introduction of the toolkit, and 6.2% of
dementia cases afterwards, an absolute rise of 1.6%, equal to a 35% increase in the number of DLB cases diagnosed
when using the toolkit (χ2 = 4.2, P = 0.041).
The number of PD patients diagnosed with PDD was not found overall to be significantly different when using the
toolkit: 9.6% of PD cases before and 8.2% of cases after its introduction (χ2 = 1.8, P = 0.18), though the ages of PD
patients assessed after the toolkit’s introduction were lower (73.9 years vs 80.0 years, t = 19.2, p < 0.001).
Conclusion: Introduction of the assessment toolkit was associated with a significant increase in the rate of DLB
diagnosis, suggesting that a structured means of assessing symptoms and clinical features associated with DLB can
assist clinicians in recognising cases. The assessment toolkit did not alter the overall rate of PDD diagnosis,
suggesting that alternate means may be required to improve the rate of diagnosis of dementia in Parkinson’s
disease.
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Introduction
Lewy body dementia, consisting of dementia with Lewy
bodies (DLB) and Parkinson’s disease dementia (PDD),
is the second most common neurodegenerative demen-
tia in older people and comprises 15–20% of dementia
cases in pathological studies [1, 2].
However, the clinical prevalence of Lewy body demen-
tia (LBD) is found to be much less, with systematic re-
views reporting the prevalence of DLB to be 4.2–5% [3,
4] and PDD to be 3.6%, of all dementia cases [5]. In
addition, our group investigated the diagnostic rate of
DLB in clinical practice in two regions in the UK and
found it to be 4.6% [6]; hence, DLB is likely to be under-
diagnosed in these regions. Our group also found the
proportion of Parkinson’s disease (PD) cases with de-
mentia (i.e. PDD) was 9.7%, also below that expected
when compared with the prevalence of between 20 and
30% reported in a systematic review [5]. We now sample
a proportion of the same services included in the earlier
report, assessing diagnostic rates before and after the
introduction of an assessment toolkit designed to im-
prove recognition and diagnosis of DLB and PDD.
Consensus diagnostic criteria for DLB [7, 8] and PDD
[9, 10], aid clinicians in assessing patients with suspected
Lewy body dementia. These criteria depend on eliciting
a number of symptoms and clinical signs supported by
the use of biomarkers, although a definitive diagnostic
test is not yet available. DLB in particular is a heteroge-
neous condition with variable presenting features [11],
often co-existing with significant Alzheimer’s pathology
which can make diagnosis challenging, as core features
may be masked leading to a diagnosis of AD [12, 13]. In
a recent autopsy study, of the 30 cases with DLB (alone
or mixed with AD), only 6 were correctly identified clin-
ically as having DLB pathology, with the majority diag-
nosed as either AD or mixed AD and vascular dementia
[14]. Delays in diagnosis can also occur, with higher at-
tendances at clinic, a higher number of imaging tests re-
quired and more alternative diagnoses given to those
with DLB than with other types of dementia [15, 16].
A diagnostic toolkit could provide a structured frame-
work for the assessment of patients suspected of Lewy
body dementia and might assist in raising the clinical
diagnostic rate closer to the rates of LBD that are re-
ported at autopsy. Whilst there are examples of struc-
tured assessment tools used in the diagnosis of
dementia, the efficacy of such methods is yet to be
assessed. In other medical disciplines, for example paedi-
atrics and dermatology, toolkits have been found to be
beneficial in diagnosis and in improving knowledge and
behaviour when used as a diagnostic framework [17, 18].
Here we investigate whether the introduction of such
a diagnostic toolkit to clinicians in secondary care im-
proved the diagnostic rates of LBD.
Methods
Objectives
The primary objective of the study was to assess whether
the introduction to NHS clinical services of a diagnostic
toolkit would be associated with a change in the clinical
diagnostic rates of DLB and PDD.
Study design
We undertook a prospective study, examining preva-
lence rates for DLB and PDD diagnosis covering an 18-
month period before and after the introduction of the
assessment toolkit.
Services within two NHS Trusts in the North East
and East Anglia of the UK, the same regions that
were previously sampled for DLB and PDD diagnostic
rates [6]. The services consisted of four memory
clinics that were assessed for the rate of DLB diagno-
sis, these four services were a part of the nine ser-
vices sampled in the previously performed prevalence
study (Kane et al.) [6]. In addition, three movement
disorders (or PD) clinics were assessed for the rate of
diagnosis of PDD; similarly, these three services
formed part of the five services sampled in the previ-
ously performed prevalence study.
The toolkit was based on the established diagnostic
criteria for DLB and PDD [19, 20] and was developed
following piloting in a service not involved in the current
study. The toolkits set out the diagnostic criteria for
PDD and DLB together with the questions to ask either
the patient or carer to assess whether the patient fulfils
such criteria. A systematic method for assessing for par-
kinsonism was also included. The entire toolkit and de-
tails of the pilot study can be found through the website
link in the ‘Availability of data and materials’ section
below.
The assessment toolkit was introduced to clinicians at
an initial site visit, before a training session on how to
apply the toolkit in clinical scenarios was provided by
the study investigators, including where required teach-
ing sessions on examining for parkinsonism. The study
team provided further support on the use of the toolkit
during the course of the study when requested by
clinicians.
Procedure
The notes of all subjects seen in these services were
reviewed to identify patients with a diagnosis of demen-
tia (for DLB prevalence), or those with a diagnosis of PD
(for PDD prevalence), attending each participating ser-
vice, for an 18-month period before the introduction of
the toolkit and then an 18-month period after its
introduction.
Surendranathan et al. Alzheimer's Research & Therapy           (2021) 13:50 Page 2 of 8
Statistical analysis
Statistical analysis was performed using SPSS 26.0 for
Windows. Confidence intervals for prevalence were cal-
culated using the Wilson method. Mean values and pro-
portions were analysed using Student’s t test for
independent samples and χ2 test, respectively. For each




In the DLB part of the study, from the period prior to
the introduction of the toolkit, 3820 case notes were
reviewed from memory clinics and 2140 dementia cases
identified (consisting of 1460 in the North East and 680
in East Anglia). From the period after the introduction
of the toolkit, 2058 case notes were reviewed from the
same services and 1279 dementia cases detected (con-
sisting of 632 in the North East and 647 in East Anglia).
There were no significant differences in age or sex be-
tween the groups assessed prior to the introduction of
the toolkit and the group assessed after the introduction
of the toolkit (see Table 1 - Demographics).
In the PDD part of the study, from the period prior to
the introduction of the toolkit 1797 case notes were
reviewed from movement disorder or PD clinics across
the two regions, with 1130 cases of Parkinson’s disease
identified, consisting of 974 in the North East and 156 in
East Anglia. In the 18-month period following the intro-
duction of the toolkit, 3405 case notes were reviewed from
the same services, with 1967 cases of PD identified, con-
sisting of 1809 in the North East and 158 in East Anglia.
The group of PD cases sampled prior to the introduc-
tion of the toolkit was significantly older than the group
which was sampled after the introduction of the toolkit,
by a mean of 6.1 years (P < 0.001). This earlier group also
had a slightly higher proportion of females (p = 0.048),
see Table 1.
Dementia with Lewy bodies
Before the introduction of the toolkit, the proportion of
dementia cases diagnosed with DLB was found to be
4.6% (95% confidence interval (CI) 3.8% to 5.5%).
Following the introduction of the toolkit, DLB was diag-
nosed in 6.2% (CI 5.0% to 7.6%) of dementia cases (see
Fig. 1). This is an absolute rise of 1.6%, equal to a 35%
increase in the cases diagnosed compared to the baseline
(χ2 = 4.16, P = 0.041).
With respect to the different regions, in the North
East, there was a significant increase from 5.3 to 9.7%
(χ2 = 13.2, P < 0.001) after the toolkit was introduced. In
East Anglia, however, there was no significant change,
with a rate of 2.9% and 2.8% (χ2 = 0.30, P = 0.86), pre and
post introduction of the toolkit, respectively.
Since the rate of DLB diagnosed differentially increased
between the regions, we looked at other diagnostic cat-
egories for dementia to see if this would shed insights into
why the diagnostic rates increased in one region, but not
the other. The diagnosis rates of the different subtypes as
recorded within each region can be seen in Fig. 2.
Following the introduction of the toolkit, the diagnosis
of dementia subtypes across both regions showed Alz-
heimer’s disease and mixed dementia as the commonest
diagnosed across both regions, with Alzheimer’s re-
corded as having a higher rate in the North East and
mixed dementia recorded higher in East Anglia.
Parkinson’s disease dementia
In the initial survey, prior to the toolkits’ introduction,
the number of PD patients diagnosed with PDD was
found to be 9.6% (CI 8.1% to 11.5%). Following the
introduction of the toolkit, PDD was diagnosed in 8.2%
(CI 7.1% to 9.5%), which did not represent a statistically
different change (χ2 = 1.79, P = 0.18)—see Fig. 3.
There were contrasting results in the different regions.
In East Anglia, there was a significant increase from 4.5
to 13.3% (χ2 = 7.49, P = 0.006). In the North East, how-
ever, there was a significant decrease from 10.5 to 7.8%
(χ2 = 5.7, P = 0.017).
Comparison with earlier prevalence study
A comparison of the results here with those from the
earlier prevalence study shows that the services sampled
in this study had similar DLB rates and PDD rates prior
to the introduction of the assessment toolkit as the ser-
vices sampled in the larger prevalence study [6] (see
Table 1 Demographics
Pre Post Statistic P
Age (mid screening period) Years (SD) Years (SD) t test
DLB study 82.2 (7.9) 82.1 (7.5) 0.18 0.88
PDD study 80.0 (7.1) 73.9 (10.2) 19.2 < 0.001
Sex Male/female (%male) Male/female (%male) χ2
DLB study 865/1275 (40.4%) 499/780 (39.0%) 0.66 0.42
PDD study 666/461 (59.1%) 1233/734 (62.7%) 3.89 0.048
Age and sex comparison between subjects (pre and post introduction of the assessment toolkit) for both DLB and PDD parts of the study
Surendranathan et al. Alzheimer's Research & Therapy           (2021) 13:50 Page 3 of 8
Fig. 4), with DLB and PDD rates the same or very similar
to the larger samples.
Discussion
DLB diagnosis rates
The introduction of an assessment toolkit was associated
with a significant increase in the rate of DLB diagnosis,
suggesting that a structured means of assessing patients
for DLB together with an increased awareness of DLB
criteria during clinician assessment may increase the
likelihood of diagnosis. This may reflect the heterogen-
eity of the condition at presentation, as core features
may be obscured by other more troublesome clinical
complaints such as psychiatric disturbance or falls. Yet
Fig. 1 DLB diagnosis as a proportion of all dementia cases, before and after the introduction of an assessment toolkit for the diagnosis of DLB in
the two regions sampled as well as overall (error bars represent 95% confidence intervals)
Fig. 2 Dementia subtypes in the two regions after the introduction of the toolkit. AD, Alzheimer’s; FTD, fronto-temporal dementia; Mix, mixed
dementias (excluding DLB); Uns, dementia subtype unspecified; Vas, vascular dementia
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direct questioning may reveal the underlying Lewy body
disorder, with for example targeted questioning for rapid
eye movement (REM) sleep behaviour disorder or fluctu-
ating cognition. DLB is recognised as a challenging dis-
order to diagnose: DLB patients receive more alternative
diagnoses and experience a longer length of time before
receiving a final diagnosis [16]. Care-givers report the
majority of patients see more than three doctors before
a Lewy body diagnosis is made [15]. A DLB assessment
toolkit may therefore be the support that clinicians need
to help diagnose DLB quickly and accurately. In
addition, a general increased knowledge and awareness
Fig. 3 PDD diagnosis as a proportion of all PD cases, before and after the introduction of an assessment toolkit for the diagnosis of PDD in the
two regions sampled as well as overall (error bars represent 95% confidence intervals)
Fig. 4 DLB and PDD rates pre and post introduction of the assessment toolkit compared to those reported in the earlier prevalence study [6]
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of DLB following-on from the study team’s site visits
and training sessions could also have contributed to the
increase in diagnosis.
Despite the overall increase in diagnostic rates following
the introduction of the assessment toolkit, there were re-
gional differences found. In East Anglia, there was a no
significant change (2.9% to 2.8%, P = 0.86) in diagnostic
rates of DLB, whereas in the North East, there was an ab-
solute increase of 4.4% (5.3% to 9.7%, P < 0.001).
Factors, such as a lower level of engagement in the
toolkit, may have affected the outcome in East Anglia.
In addition, services in East Anglia recorded more de-
mentia patients with a ‘mixed’ subtype (47.8%) than an
Alzheimer’s dementia (AD) subtype (33.8%). A European
wide systemic review of the prevalence of different de-
mentia subtypes in those older than 65 found the preva-
lence of AD to be 53.7% [21]. A UK survey of dementia
prevalence commissioned by the Alzheimer’s Society
found AD to make up 62% of all dementia cases [22].
Both of these figures are higher than that reported for
Alzheimer’s dementia in East Anglia. Yet 47.8% of de-
mentia cases were found to be ‘mixed’ in East Anglia,
and this excluded cases which specifically stated a com-
bination of DLB with another subtype, which were sim-
ply recorded as DLB. This could mean some DLB cases
were recorded as ‘mixed’ reflecting diagnostic uncer-
tainty on the part of the clinician. This could also ex-
plain a lower rate of AD. Indeed the percentage of cases
recorded as mixed was much higher than the 10% re-
ported by the Alzheimer’s Society [22].
The higher increase of DLB diagnosis in this study was
in the North East which also had the higher diagnosis
rate before the introduction of a toolkit, suggesting the
toolkit may not necessarily have the biggest benefit to
services with the lowest rates. It may be that the toolkit
enhances diagnostic performance in clinicians already
aware of, and confident in, diagnosing DLB. Those less
certain about diagnosis may require additional support
and more extensive training in its use, rather than sim-
ply introducing it directly into practice.
These results also suggest that clinical prevalence may
be higher than previously recorded. Systematic reviews
report the prevalence of DLB to be 4.2–5% [3, 4], yet the
levels detected in this study in the North East were 9.7%
(CI 7.6% to 12.2%), nearing the rate of DLB seen in aut-
opsy studies of 15% [2]. In the absence of a simple diag-
nostic test, a structured assessment toolkit may be what
is required to improve detection of DLB, leading to the
significant benefits of early and accurate diagnosis for
patients and their carers.
Correctly diagnosing DLB is important for patients
and their carers [23]. Failure to recognise autonomic
symptoms secondary to the disorder such as orthostatic
hypotension which can cause falls or bladder
dysfunction that harshly affects independence and confi-
dence can have severe effects on a patient’s quality of life
[24]. The use of anti-psychotics can lead to worsening of
an undiagnosed movement disorder and in severe
cases can be fatal secondary to akinetic crisis [25].
Hence, improving detection will be significant for this
group of patients.
PDD diagnostic rates
In contrast to DLB, the assessment toolkit did not alter
the overall rate of PDD diagnosis.
It was nevertheless notable that in East Anglia, there
was a significant increase in PD dementia diagnosis rates
following the introduction of the toolkit—an increase of
4.5% to 13.3%, or an absolute rise of 8.8%. This large
rise, nearly trebling the rate of diagnosis, may indicate
an assessment toolkit could assist in services where diag-
nosis rates are lower, as the rate in East Anglia (4.5%)
was much lower than in the North East (10.5%) prior to
its introduction. However, a limiting factor in this find-
ing is the relatively small sample group in East Anglia,
with only 158 PD patients compared with 1809 in the
North East. The significant reduction in diagnostic rates
within the larger group of PD patients in the North East
nullified the large improvement in East Anglia and leads
to the conclusion that there is no associated rate rise in
PDD diagnosis from the introduction of the toolkit.
Reasons why no overall improvement in diagnosis was
recorded may include clinicians’ level of engagement in
the study and hence utilisation of the toolkit. A qualita-
tive process evaluation on implementation of the toolkits
will be reported separately. Another factor may be that
the group surveyed following the introduction of the
toolkit was younger (73.9 years) than the group studied
in the initial pre-toolkit survey (80.0 years). It is well
recognised that older age is associated with higher rates
of dementia, including in PD [26].
In addition, Parkinson’s disease patients already have
an established Lewy body disorder so the difficulties in
the diagnosis of PDD are probably very different to that
of differentiating DLB from other dementia subtypes.
The diagnosis of PDD requires the recognition of a de-
mentia syndrome, which can be facilitated by a cognitive
assessment and a collateral history of functional decline.
Notably, difficulties in integrating a formal cognitive as-
sessment into an initial patient assessment were reported
in the pilot trial of the toolkit [19]. Even when these are
carried out, the diagnosing clinician may remain uncer-
tain about the degree of severity of such impairments
and also the degree to which they can be attributed to
motor, rather than cognitive deficits. There may also be
a reluctance to formally diagnose dementia [16] because
of its stigmatising effect. None of these potential barriers
to the diagnosis of dementia in PD is likely to be affected
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solely by the introduction of a structured assessment
toolkit. An alternate means may be required to improve
the rate of diagnosis of dementia in Parkinson’s disease.
Limitations
The relatively small PD group size in East Anglia is a
limitation of the study, meaning the large rise in diag-
nostic rate in this region is difficult to interpret. It is an-
other limitation that only seven services were sampled in
total. However, the diagnostic rates recorded prior to
the introduction of the assessment toolkit were very
similar to that seen in the larger prevalence study of 14
services [6], suggesting the services sampled here were a
good reflection of that larger group.
Conclusions
The introduction of an assessment toolkit was associated
with a significant increase in the diagnosis of DLB, but this
may be because clinicians already confident in diagnosing
DLB are able to benefit from the introduction of a simple
toolkit to reference. The high number of mixed dementia
cases highlights diagnostic uncertainty amongst some cli-
nicians, and those who are less confident in diagnosing
DLB may gain confidence from greater training on the use
of the toolkit and may lead to even higher diagnosis rates.
Contrasting changes in diagnosis rates of PDD were
observed regionally following the introduction of the
toolkit, which may be explained by the small samples
size in East Anglia, but maybe also by the differing diag-
nostic process for diagnosing dementia in PD as com-
pared to making a DLB subtype diagnosis.
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